Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Yuan Zhuang, Chang Liu, Jiaqing Liu & Guang Li. (2020) Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle. OncoTargets and Therapy 13, pages 83-94.
Read now
Read now
Orgilmaa Regzedmaa, Hongbing Zhang, Hongyu Liu & Jun Chen. (2019) Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges. OncoTargets and Therapy 12, pages 4605-4620.
Read now
Read now
Sheik Emambux, Gaelle Tachon, Audelaure Junca & David Tougeron. (2018) Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opinion on Biological Therapy 18:5, pages 561-573.
Read now
Read now
Nagashree Seetharamu, Isabel R Preeshagul & Kevin M Sullivan. (2017) New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab. Lung Cancer: Targets and Therapy 8, pages 67-78.
Read now
Read now
Wenjie Guo, Sihan Liu, Xiaoli Zhang, Yating Chen, Ruolan Qian, Ziyuan Zou, Xin Chen & Peng Luo. (2017) The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer. Drug Design, Development and Therapy 11, pages 3367-3376.
Read now
Read now
Reginald M Gorczynski & Fang Zhu. (2017) Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. Cancer Management and Research 9, pages 601-609.
Read now
Read now
Articles from other publishers (31)
Steven Grudman, J Eduardo Fajardo & Andras Fiser. (2023) Optimal selection of suitable templates in protein interface prediction. Bioinformatics 39:9.
Crossref
Crossref
Se‐Hoon Lee, Yeongmin Kim, Bu‐Nam Jeon, Gihyeon Kim, Jinyoung Sohn, Youngmin Yoon, Sujeong Kim, Yunjae Kim, Hyemin Kim, Hongui Cha, Na‐Eun Lee, Hyunsuk Yang, Joo‐Yeon Chung, A‐Reum Jeong, Yun Yeon Kim, Sang Gyun Kim, Yeonhee Seo, Sehhoon Park, Hyun Ae Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Hansoo Park & Kyoung Wan Yoon. (2023)
Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8
+
T Cells
. Advanced Science 10:17.
Crossref
Crossref
Liping Pan, Juan Han & Ming Lin. (2023) Targeting breast cancer stem cells directly to treat refractory breast cancer. Frontiers in Oncology 13.
Crossref
Crossref
Yunfeng Ni, Jie Lei, Wan Huang, Jian Wang, Haihua Guo, Feng Lv, Shuhong Kang, Ke Lan & Tao Jiang. (2023) Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis. Frontiers in Oncology 13.
Crossref
Crossref
Shengjie Tang, Chao Qin, Haiyang Hu, Tao Liu, Yiwei He, Haiyang Guo, Hang Yan, Jun Zhang, Shoujun Tang & Haining Zhou. (2022) Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells 11:3, pages 320.
Crossref
Crossref
Manzoor A. Mir, Shazia Sofi & Hina Qayoom. 2022. Combinational Therapy in Triple Negative Breast Cancer. Combinational Therapy in Triple Negative Breast Cancer
149
176
.
Lei Zhang, Huanhuan Liu, Ye Tian, Huina Wang & Xueying Yang. (2021) A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
Dan Yan, H. Shelton Earp, Deborah DeRyckere & Douglas K. Graham. (2021) Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. Cancers 13:22, pages 5639.
Crossref
Crossref
Tsung-Yu Tsai, Ming-Ting Huang, Pei-Shan Sung, Cheng-Yuan Peng, Mi-Hua Tao, Hwai-I Yang, Wei-Chiao Chang, An-Suei Yang, Chung-Ming Yu, Ya-Ping Lin, Ching-Yu Bau, Chih-Jen Huang, Mei-Hung Pan, Chung-Yi Wu, Chwan-Deng Hsiao, Yi-Hung Yeh, Shiteng Duan, James C Paulson & Shie-Liang Hsieh. (2021) SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection. Journal of Clinical Investigation 131:11.
Crossref
Crossref
Mengying He, Tao Yang, Yuhan Wang, Mengyuan Wang, Xingye Chen, Dawei Ding, Yiran Zheng & Huabing Chen. (2021) Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy. Advanced Healthcare Materials 10:9.
Crossref
Crossref
Andreas Koulouris, Christos Tsagkaris & Michail Nikolaou. (2021) Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. Toxins 13:2, pages 149.
Crossref
Crossref
Pei-Pei Zhang, Juan Wang, Da-Zhi Ding, Li Zhang, Chun Cheng & Da-Ke Chen. (2021) Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer. Medicine 100:35, pages e27121.
Crossref
Crossref
Thachanun Porntharukchareon, Borwonkhun Tontivuthikul, Nattaya Sintawichai & Panudda Srichomkwun. (2020) Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report. Journal of Medical Case Reports 14:1.
Crossref
Crossref
Laura Evangelista, Matteo Sepulcri & Giulia Pasello. (2020) PET/CT and the Response to Immunotherapy in Lung Cancer. Current Radiopharmaceuticals 13:3, pages 177-184.
Crossref
Crossref
Bernardo L Rapoport, Annette J Theron, Daniel A Vorobiof, Lizanne Langenhoven, Jacqueline M Hall, Ronwyn I Van Eeden, Teresa Smit, Sze-Wai Chan, Michael C Botha, Johann I Raats, Margriet De Necker & Ronald Anderson. (2020) Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer. Lung Cancer Management 9:3.
Crossref
Crossref
David Chardin, Marie Paquet, Renaud Schiappa, Jacques Darcourt, Caroline Bailleux, Michel Poudenx, Aurélie Sciazza, Marius Ilie, Jonathan Benzaquen, Nicolas Martin, Josiane Otto & Olivier Humbert. (2020) Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. Journal for ImmunoTherapy of Cancer 8:2, pages e000645.
Crossref
Crossref
Mary-Ann N. Jallad, Abdo R. Jurjus, Elias A. Rahal & Alexander M. Abdelnoor. (2020) Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model. Frontiers in Oncology 10.
Crossref
Crossref
Liqun Yuan, Jianrong Ye & Di Fan. (2020) The B7-H4 gene induces immune escape partly via upregulating the PD-1/Stat3 pathway in non-small cell lung cancer. Human Immunology 81:5, pages 254-261.
Crossref
Crossref
Chengsong Cao, Yong Liu, Qun Wang, Jing Zhao, Ming Shi & Junnian Zheng. (2020) Expression of CHPF modulates cell proliferation and invasion in lung cancer. Brazilian Journal of Medical and Biological Research 53:5.
Crossref
Crossref
Xiaoguang Qi, Chunyan Qi, Tao Wu & Yi Hu. (2020) CSF1R and HCST: Novel Candidate Biomarkers Predicting the Response to Immunotherapy in Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment 19, pages 153303382097066.
Crossref
Crossref
Nelson Gil, Eduardo J. Fajardo & Andras Fiser. (2019) Discovery of receptor‐ligand interfaces in the immunoglobulin superfamily. Proteins: Structure, Function, and Bioinformatics 88:1, pages 135-142.
Crossref
Crossref
Kongju Wu, Ming Yi, Shuang Qin, Qian Chu, Xinhua Zheng & Kongming Wu. (2019) The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Experimental Hematology & Oncology 8:1.
Crossref
Crossref
Qianqian Gao, Xuan Dong, Qumiao Xu, Linnan Zhu, Fei Wang, Yong Hou & Cheng‐chi Chao. (2019) Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy. Cancer Medicine 8:9, pages 4254-4264.
Crossref
Crossref
Stephanie Crawford Andrews & Marianne Davies. 2019. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners
65
84
.
Zehuan Li, Yiran Qiu, Weiqi Lu, Ying Jiang & Jin Wang. (2018) Immunotherapeutic interventions of Triple Negative Breast Cancer. Journal of Translational Medicine 16:1.
Crossref
Crossref
Robert Wilson, David A. Menassa, Alexander J. Davies, Sophia Michael, Joanna Hester, Wilhelm Kuker, Graham P. Collins, Judith Cossins, David Beeson, Neil Steven, Paul Maddison, Simon Rinaldi, Saiju Jacob & Sarosh R. Irani. (2018) Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Annals of Clinical and Translational Neurology 5:5, pages 640-645.
Crossref
Crossref
Dandan Xu, Guoliang Jin, Dafei Chai, Xiaowan Zhou, Weiyu Gu, Yanyun Chong, Jingyuan Song & Junnian Zheng. (2018) The development of CAR design for tumor CAR-T cell therapy. Oncotarget 9:17, pages 13991-14004.
Crossref
Crossref
Filippo de Marinis, Fortunato Ciardiello, Paul Baas, Lucio Crinò, Giuseppe Giaccone, Francesco Grossi, Matthew D. Hellmann, Tony S.K. Mok, Hervè Lena, Luis Paz-Ares, Delvys Rodriguez-Abreu, Joachim Von Pavel & Cesare Gridelli. (2018) 30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO Open 3:4, pages e000298.
Crossref
Crossref
Allison S. Cohen, Farah K. Khalil, Eric A. Welsh, Matthew B. Schabath, Steven A. Enkemann, Andrea Davis, Jun-Min Zhou, David C. Boulware, Jongphil Kim, Eric B. Haura & David L. Morse. (2017) Cell-surface marker discovery for lung cancer. Oncotarget 8:69, pages 113373-113402.
Crossref
Crossref
Khadijah A. Mitchell, Adriana Zingone, Leila Toulabi, Jacob Boeckelman & Bríd M. Ryan. (2017) Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans. Clinical Cancer Research 23:23, pages 7412-7425.
Crossref
Crossref
Kailing Wang, Shan Shan, Zongjun Yang, Xia Gu, Yuanyuan Wang, Chunhong Wang & Tao Ren. (2017) IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model. Oncotarget 8:40, pages 68571-68582.
Crossref
Crossref